Articles related to BREAST CANCER

With just a few exceptions (p.I157T, p.S428F, and p.T476M), CHEK2 PVs were linked to comparable cancer phenotypes regardless of the variation type. Although CHEK2 PVs were linked to breast, kidney, and thyroid malignancies, they were not linked to colorectal cancer. The prevalent p.I157T, p.S428F, and p.T476M alleles have a weaker connection with breast cancer compared to other CHEK2 PVs and were not related with non-breast malignancies. These findings might help with genetic counseling and care for those with CHEK2 PVs.

A 29-year-old woman bought a genetic test that includes BRCA analysis. She comes to you with the results and asks for guidance. The results are negative for BRCA1 and BRCA2, but she has a positive family history for breast cancer. What do you advise?

This trial included 33 patients with clinical node-positive locally advanced breast cancer who underwent NET and breast surgery. MRI exams were performed before the first treatment regimen, at least two months after the first treatment cycle but prior to crossing-over, and immediately before surgery. MRI did not demonstrate sufficient diagnostic performance to avoid surgical axillary staging in the authors’ analysis.

The prospective, open-label, single-arm, phase 2 TUXEDO-1 trial enrolled patients with HER2-positive breast cancer and newly diagnosed untreated brain metastases or brain metastases progressing after previous local therapy. Patients received trastuzumab deruxtecan intravenously at the standard dose of 5.4 mg per kg bodyweight once every 3 weeks. Fifteen patients received at least one dose of study drug. Two patients (13.3%) had a complete intracranial response, nine (60%) had a partial intracranial response and three (20%) had stable disease as the best intracranial response. There were no new safety signals.

The Stockholm Tamoxifen (STO-3) trial conducted from 1976 to 1990 included 462 postmenopausal patients with lymph node-negative breast cancer. This secondary analysis of trial data (including a 2014 tumor tissue assessment with immunohistochemistry and Agilent microarrays) looked for long-term survival benefit with tamoxifen. The authors conclude that patients with luminal A tumor subtype appeared to have a long-term (i.e., 15-year) benefit from tamoxifen therapy, and patients with luminal B subtype appeared to have an early benefit (i.e., 5 years) from therapy, when the risk of distant metastatic disease was high.

Guideline-directed binary distinctions between HER2-positive and HER2-negative breast cancer have guided physicians’ treatment decisions for quite some time, but new research suggests that patients with HER2-2+, ISH-negative breast cancer present a clinical picture closer to that of patients with HER2-positive breast cancer, offering up a new nomenclature, HER2-low.